Informing parents of newborns with sickle cell trait detected at neonatal screening: A northern France experience
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31174 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Malo Freppel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lille University Hospital (CHU Lille), Lille, France. Hauptthemen laut MEDLINE: Neonatal Screening, Sickle Cell Trait, Parents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regional Association for Child Disability Screening and Prevention.
Abstract (Originalsprache)
Neonatal screening for sickle cell disease (SCD) in France, targeted since 1995, indirectly detects newborns with sickle cell trait (SCT). Information about carrier status must be communicated to families in accordance with the 2006 National Consultative Ethics Committee recommendations; however, no national protocol for this exists. In the departments of Nord and Pas‐de‐Calais, the Regional Neonatal Screening Center transmits this information through a general practitioner (GP). This study aimed to assess the success rate of local practices in transmitting SCT information to parents. The secondary objectives included explaining transmission failures, evaluating post‐information couple screening rates, and conducting a nationwide evaluation of SCT information dissemination. In this retrospective, multicenter study, family doctors were surveyed regarding newborns screened for SCT between January 1 and December 31, 2020, in the Nord and Pas‐de‐Calais departments. Among the 260 screened newborns, 197 were eligible for analysis. Results showed that 31.2% of newborns with SCT had their GP definitively sharing information with their parents. Based on this information, subsequent parental screening accounted for 13.6% of cases. The reasons cited by the GP for failing to convey information included elusive families (52.5%), unfamiliarity or refusal of the role (35%), limited SCD knowledge (25%), and ethical considerations (12.5%). This study highlights the difficulty and heterogeneity in transmitting carrier status information to parents of newborns with SCT. Our findings could serve as a foundation for the development of new methods for information transmission, given the generalization of neonatal screening for SCD by the French National Authority for Health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lille University Hospital (CHU Lille), Lille, France.
- Regional Neonatal Screening Center (CRDN Hauts-de-France), Lille University Hospital (CHU Lille), Lille, France.
- Perinatal Screening Laboratory, Center for Biology and Pathology, Lille University Hospital (CHU Lille), Lille, France.
ORCID-Profile: Malo Freppel
Förderung
- Regional Association for Child Disability Screening and Prevention
Zitieren
APA
Freppel, M., Mention, K., Renom, G., Lambilliotte, A., & Barbati, M. (2024). Informing parents of newborns with sickle cell trait detected at neonatal screening: A northern France experience. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31174
Vancouver
Freppel M, Mention K, Renom G, Lambilliotte A, Barbati M. Informing parents of newborns with sickle cell trait detected at neonatal screening: A northern France experience. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31174
BibTeX
@article{Freppel2024,
author = {Freppel, Malo and Mention, Karine and Renom, Gilles and Lambilliotte, Anne and Barbati, Mélissa},
title = {Informing parents of newborns with sickle cell trait detected at neonatal screening: A northern France experience},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31174}
}
EUVIMED